GEN1047 for Solid Tumors - First in Human (FIH) Trial
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
In brief
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: * The side effects seen with GEN1047 * What the body does with GEN1047 once it is administered * What GEN1047 does to the body once it is administered * How well GEN1047 works against solid tumors The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.
Key facts
- Study ID
- NCT05180474
- Run by
- Genmab
- People needed
- 179
- Starts
- 2021-12-13
- Expected to finish
- 2026-03-25
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Institut Curie — Paris, France
- Hôpital Cochin — Paris, France
- CHU Poitiers - Hôpital la Milétrie — Poitiers, France
- UCLA Department of Medicine Hematology Oncology — Los Angeles, California, United States
- Yale University - Yale Cancer Center — New Haven, Connecticut, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Case Western Reserve University — Cleveland, Ohio, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Antwerp University Hospital — Edegem, Belgium
- Universitair Ziekenhuis Leuven — Leuven, Belgium
- Rigshospitalet (Copenhagen University Hospital) — Copenhagen, Denmark
- CHU de Besancon — Besançon, France
- Institut Bergonié — Bordeaux, France
- Centre Léon Bérard — Lyon, France
- Institut du Cancer de Montpellier — Montpellier, France
- Institut Claudius Regaud — Toulouse, France
- Institut Gustave Roussy — Villejuif, France
- IEO Istituto Europeo di Oncologia — Milan, Italy
- Fondazione IRCCS San Gerardo dei Tintori — Monza, Italy
- University Medical Center Groningen — Groningen, Netherlands
- Radboudumc — Nijmegen, Netherlands
- Erasmus Medisch Centrum — Rotterdam, Netherlands
- Med-Polonia Sp. z o.o — Poznan, Poland
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.